Savara is currently conducting a pivotal Phase 3 clinical trial, IMPALA, of Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), IMPALA-X, an open-label, safety extension study in aPAP, and a Phase 2a clinical study, OPTIMA, of Molgradex for the treatment of nontuberculous mycobacterial (NTM) infection.
Savara is also conducting a pivotal Phase 3 study, AVAIL, of AeroVanc for the treatment of MRSA in Cystic Fibrosis patients in the U.S. and Canada.
We are advancing a pipeline of novel inhalation therapies for the treatment of severe pulmonary conditions.
We focus on rare respiratory diseases in order to give patients with unmet medical needs better treatment options.
Visit the AeroVanc website to learn more about MRSA in Cystic Fibrosis, AeroVanc and our pivotal Phase 3 AVAIL study
Visit our PAP portal where patients and doctors can learn more about this disease
Savara Nasdaq Opening Bell Ceremony - July 23, 2018×